AngioDynamics Earnings Call Highlights Med Tech Momentum

Angiodynamics, Inc. ((ANGO)) has held its Q3 earnings call. Read on for the main highlights of the call.

AngioDynamics’ latest earnings call struck a decidedly upbeat tone, with management emphasizing robust commercial momentum across its Med Tech platforms and the confidence to lift both revenue and adjusted EBITDA guidance. While tariffs, manufacturing shifts, and higher operating costs are weighing on margins and cash, executives stressed that accelerating adoption of Auryon, AlphaVac, AngioVac, and NanoKnife is reshaping the business toward faster growth.

Steady Quarterly Growth and Upgraded Full-Year Outlook

AngioDynamics posted Q3 revenue of $78.4 million, up 8.9% year over year, underscoring resilient demand despite macro uncertainty and operational headwinds. Management used the print to raise FY 2026 net sales guidance to $313.5–$315.5 million and lifted adjusted EBITDA expectations to $10–$12 million, signaling growing confidence in the underlying trajectory.

Med Tech Becomes the Growth Engine

The Med Tech segment delivered $37.3 million of revenue in Q3, jumping 19% from a year earlier and now contributing 48% of total company sales versus 44% previously. This shift toward higher-growth, higher-margin therapies highlights the strategic pivot away from slower legacy lines and positions the company for structurally better profitability over time.

Auryon Extends Its Double-Digit Growth Streak

Auryon laser system revenue climbed 17.9% year over year to $16.3 million, marking the 19th consecutive quarter of double-digit growth for the platform. Management credited new product extensions and rising hospital penetration, adding that stronger price and volume mix point to deepening clinical adoption rather than one-off wins.

Mechanical Thrombectomy Sees Rapid Uptake

Combined revenue for AlphaVac and AngioVac mechanical thrombectomy products reached $11.5 million, up 17.9% year over year as physicians increasingly favor minimally invasive options. AlphaVac stood out with $4.4 million in sales, up 47.4% year over year and more than 24% sequentially, while AngioVac grew 5% to $7.2 million as the company also kicked off the pivotal APEX-Return trial aimed at a potential 2027 approval catalyst.

NanoKnife Gains from Strong Volumes and Regulatory Tailwinds

NanoKnife revenue rose 21% year over year to $7.6 million, driven by roughly 20% growth in disposable probe volumes and a 24.9% rise in capital equipment sales. The product received a further boost from the new CPT 1 reimbursement code effective in January and expanded European soft tissue ablation indications across the liver, pancreas, kidney, and prostate, which together should support broader global usage.

Profitability Edges Higher on Adjusted Basis

Adjusted EBITDA improved to $1.8 million in Q3 from $1.3 million a year earlier, reflecting better operating leverage from higher Med Tech mix. The adjusted net loss narrowed slightly to $3.0 million, or $0.07 per share, though the company remains loss-making on this basis despite progress, and management continues to point to Q4 as a seasonal cash and profit high point.

Commercial Execution and Training Fuel Demand

Executives highlighted strong commercial execution as a key driver, noting new hospital account wins and rising utilization within existing customers across core platforms. Training and clinical education programs are helping accelerate physician adoption, with management pointing to growing procedure volumes and recurring demand as evidence that the commercial model is gaining traction.

Tariffs and Transition Costs Squeeze Gross Margins

Gross margin slipped to 52.9% in Q3, a decline of 110 basis points year over year, as tariffs and manufacturing transition expenses weighed on profitability. Management acknowledged inflation and energy costs as additional pressures, underscoring that near-term margin performance will be shaped by macro forces as much as by internal efficiency initiatives.

Rising Tariff Expense Adds a New Cost Layer

Tariff expense totaled $1.3 million in Q3 and is expected to reach $4–$6 million for FY 2026, a notable headwind given there were no such expenses in the comparable period last year. Leaders cautioned that inflationary and energy-related cost risks remain fluid and difficult to forecast, suggesting investors should anticipate some continued volatility in reported margins.

Inventory Build Weighs on Cash, Despite Q4 Tailwind

Cash on hand declined to $37.8 million at the end of February from $41.6 million in late November, largely reflecting a $3.1 million cash outflow tied to operations and planning. The company is accelerating inventory to offset sterilization vendor shutdowns, a move expected to consume $3–$5 million of cash in the second half and potentially push FY 2026 cash flow slightly negative even as management expects strong Q4 cash generation.

Operating Expenses Remain Heavy, Leaving Net Losses

Total operating expenses reached $54.4 million in Q3, or 69% of sales, up slightly as a percentage from 68% a year earlier, underscoring the cost of growth and ongoing clinical investment. While the adjusted net loss improved modestly to $3.0 million, elevated spending levels mean the company still operates in the red on an adjusted basis and must rely on future scale and mix benefits to drive sustained profitability.

Legacy Med Device Portfolio Lags Behind

The Med Device business posted just 1.1% revenue growth in Q3 and is up only 3% year to date, sharply trailing the Med Tech segment that is powering the company’s expansion. This divergence illustrates how legacy lines are contributing little to overall top-line growth, making the Med Tech portfolio’s execution essential for hitting long-term financial targets.

Macro Uncertainty and Leadership Change Add Risk

Management acknowledged that tariffs, inflation, and energy costs introduce ongoing uncertainty, layering external risk onto the company’s own operational initiatives and cost structure. A concurrent CEO succession search adds another variable, with the leadership transition posing potential execution risk even as the strategic direction toward high-growth Med Tech remains intact.

Guidance Signals Confidence Despite Margin and Cash Headwinds

Looking ahead, AngioDynamics now expects FY 2026 sales of $313.5–$315.5 million, implying 7.1%–7.8% growth over FY 2025, with Med Tech projected to expand 15%–17% and Med Device around 1%. The company reiterated gross margin guidance of 53.5%–55.5% including $4–$6 million in tariffs, raised adjusted EBITDA guidance to $10–$12 million, and forecast a narrower adjusted loss per share of $0.30–$0.23, while keeping R&D spending near 10% of sales and highlighting a debt-free balance sheet.

The overall message from AngioDynamics’ earnings call was one of solid operational progress and rising confidence in its Med Tech growth story, tempered by clear acknowledgment of near-term cost and cash challenges. For investors, the key takeaway is that while margins and cash flow will remain under pressure from tariffs, inventory builds, and ongoing investment, the company’s expanding high-growth platforms and raised guidance suggest its strategic pivot is gaining traction.